CSTL Projected Dividend Yield
Castle Biosciences Inc ( NASDAQ : CSTL )Castle Biosciences is a commercial-stage dermatological diagnostics company focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Co.'s main product, DecisionDx-Melanoma, is a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer. Co. has commercially launched its cutaneous squamous cell carcinoma (SCC) proprietary GEP test, DecisionDx®-SCC, for use in patients with one or more risk factors. 20 YEAR PERFORMANCE RESULTS |
CSTL Dividend History Detail CSTL Dividend News CSTL Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |